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Abstract: Introduction: Renal colic can be managed by preventing the contraction movements of ureter muscles. By re-
ducing the acetylcholine in the nerve terminals, magnesium sulfate could be effective in this regard. The aim of
this study is to investigate the effect of magnesium sulfate on acute renal colic pain relief. Methods: The present
study was a double-blind clinical trial in which the patients suffering from acute renal colic were randomly
divided into 2 groups of who were received standard protocol (intravenous infusion of 0.1 mg/Kg morphine sul-
fate, 30 mg of Ketorolac, and 100 ml normal saline as placebo/15 minutes) or standard protocol plus 15 mg/Kg
of intravenous magnesium sulfate 50%/100 ml normal saline/15 minutes. Severity of patients’ pain was mea-
sured by visual analogue scale (VAS) at baseline, and 30 and 60 minutes after infusion. The collected data were
analyzed using STATA statistical software. Results: 100 cases were randomly allocated to intervention or control
group. The two groups were similar in baseline pain score and demographic characteristics. At 30 and 60 min-
utes, mean pain score was less in the intervention groupcompare to the control group. Moreover, the difference
between the two groups was statistically significant regarding the additional amount of morphine, suggesting
that the intervention group needed less additional morphine than the control group. Conclusion: The results
of this study indicated that magnesium sulfate can be used as an adjunct drug in treatment of patients suffering
from renal colic. It can reduce the pain and diminish the need for additional doses of morphine sulfate without
disturbing hemodynamic measures. However, the amounts of these effects are not clinically significant.
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1. Introduction
Urinary tract stone is a common urological disease which is
often symptomized through twinges localized to the sides
or a radicular pain towards groins and genitalia, which is
referred to as renal colic (1). Due to the obstruction of
urine flow and thereby increased ureteral wall traction, re-
nal colic is formed above the point of obstruction. This in-
creased pressure surges the production and local release of
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prostaglandins which brings about dilation of blood vessels
and diuresis, resulting in a further increase in the pressure
inside the kidney. High levels of prostaglandins, also play
a role in development of edema around the stones (2). In
addition, long isotonic contractions above the point of ob-
struction increase the production of lactic acid, contribut-
ing to slow type A and fast type C nerve fibers’ stimulation
and introduction of more pain (3). A wide variety of medi-
cations are available to treat the pain associated with acute
renal colic, each of which affect different parts of the mecha-
nisms causing the pain. For the time being, opioids and non-
steroidal anti-inflammatories drugs (NSAIDs) are the main
drugs in treatment of renal colic. Opioids are cheap and
measurable drugs; nevertheless, they are addictive and may
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have side effects such as nausea, vomiting, constipation and
drowsiness. In higher doses, they can even cause respira-
tory depression. Furthermore, opioids have no effect on the
cause of pain while they may have contractile effects on the
ureteral tone (4).NSAID, on the other hand, having a direct
effect on prostaglandins release, can bring about pain re-
lief through reducing renal pressure and diuresis. They may
also reduce the edema of ureter around the stones (2). De-
spite all these advantages, however, these drugs may induce
some secondary regulatory responses in the kidney leading
to some obstructions (5). Considering that renal colic can be
caused by peristalsis movements above the point of obstruc-
tion (1), it is hypothesized that it is possible to control the pa-
tients’ pain by preventing the contraction movements in the
ureters. By the same token, tocolytic drugs su as magnesium
sulfate can be effective in this regard. It prevents calcium
from entering the smooth muscle cell membrane, activates
adenylate cyclase and cyclic AMP, and increases the uptake
of calcium by sarcoplasmic network (6). Moreover, reduc-
ing acetylcholine in the nerve terminals, magnesium sulfate
can also decrease muscle contractions (5). Based on above-
mentioned facts, the aim of the present study is to investigate
the effect of magnesium sulfate on acute renal colic pain re-
lief.
2. Methods
2.1. Study design and setting
This randomized double-blind clinical trial was designed to
investigate the effect of intravenous magnesium sulfate in
pain relief of patients presenting to emergency department
(ED) following renal colic.
2.2. Ethical Consideration
Before being included in the study, all the patients were
provided with proper explanation about the study and they
signed the informed consent for being included. They were
free to decline to participate and to withdraw from the study.
All the research group members were required to comply
with all the provisions of the Declaration of Helsinki and Arak
University of Medical Sciences research ethics. In addition,
this project has been approved by Arak University of Medical
Sciences Ethics Committee (Code: Arakmu.ac.1394.44). This
study is registered on Iranian registry of clinical trias with
theregistration number: IRCT2016020223552N6.
2.3. Participants
Patients suffering from acute renal colic admitted to the ED
of Vali-Asr Hospital, Arak, Iran, comprised the target popula-
tion of this study. The cases were enrolled using convenient
sampling, considering some inclusion and exclusion criteria.
Inclusion criteria were as follows: being clinically diagnosed
as renal colic, being between 18 to 55 years old, and having
a pain severity > 5 based on visual analogue scale (VAS) (7).
Exclusion criteria were as follows: a history of seizure; any
heart, liver, kidney or metabolic disease; fever (oral temper-
ature > 38 Celsius), systolic blood pressure less than 90 mm
Hg, pregnancy, acute abdomen, paregoric drug consumption
3 hours before presenting to ED, history of addiction or drug
allergy, and having taken calcium channel blockers. Renal
colic was clinically defined through diagnosis of such practi-
cal benchmarks as twinges localized to the sides or radicular
pain towards groins, lower abdomen and testicles with prob-
able associated symptoms like nausea, vomiting, sweating,
pallor, dysuria, frequent urination, urgency of urination, and
blood in the urine. Suspected cases of acute coronary syn-
drome were ruled out with electrocardiography.
2.4. Randomization and Sequence generation
Patients were randomly allocated to two groups using a bal-
anced block randomization technique. To do that, they were
divided into blocks of 6. Allocation of the subjects into two
groups was done with the help of an online application called
“Sealed Envelope” (8). In this study, as a result of using bal-
anced block randomization and allocating unique codes to
each individual, “allocation concealment” was carried out.
Owing to random allocation, distribution of potential con-
founding variables is considered to be identical in the two
groups and their confounding role is controlled.
2.5. Implementation
Random allocation sequence was performed by our method-
ologist colleague through Sealed Envelope website. Eligibil-
ity assessment of the patients and their allocation was con-
ducted by the emergency resident under the supervision of
the main person responsible for the project.
2.6. Blinding
In this study, the patients and the one who was responsible
for measuring the desired outcomes in different groups were
both blind to group allocation of patients.
2.7. Intervention
An emergency medicine specialist randomly divided the pa-
tients into 2 groups. In the first group, the patients were
treated with the standard protocol of 0.1 mg/Kg of intra-
venous morphine sulfate, 30 mg of intravenous ketorolac,
and 100 ml intravenous normal saline, as placebo, within 15
minutes. In the second group, along with the standard proto-
col, 15 mg/Kg of intravenous magnesium sulfate 50% in 100
ml normal saline was additionally infused within 15 minutes
(9).
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Sex (male) 30 (60%) 29 (58%) 0.839
Age (year) 33.64±8.61 35.16±8.97 0.389
Weight (Kg) 73.72±6.25 74.84±8.21 0.444
Height (20) 172.24±5.47 171.36±6.40 0.462
Systolic BP (mmHg) 137.56±7.93 137.36±10.61 0.915
Diastolic BP(mmHg) 81.88±6.83 82.16±6.68 0.836
Pain severity (7) 9.12±0.77 9.04±0.83 0.619
Pulse rate (1/minute) 96.12±4.69 96.08±3.42 0.961
Respiratory rate(1/minute) 17.24±1.34 17.04±1.41 0.470
O2 Saturation (%) 93.88±1.79 93.72±1.77 0.654
Temperature (Celsius) 37.14±0.30 37.01±0.16 0.010
Morphine dose (mg) 6.88±0.71 6.96±0.96 0.639
Data were presented as mean ± standard deviation or number and percentage. BP: blood pressure, VAS: visual analogue scale.






Systolic blood pressure (mmHg)
Baseline 136.56 (7.98) 137.36 (10.61) 0.677
30 minute 129.28 (8.32) 131.0 (8.10)
60 minute 125.2 (6.40) 125.56 (9.42)
Diastolic blood pressure (mmHg)
Baseline 81.88 (6.83) 82.16 (6.68) 0.628
30 minute 76.88 (7.23) 78.08 (7.66)
60 minute 73.80 (6.67) 74.28 (7.76)
Pain severity (7)
Baseline 9.12 (0.77) 9.04 (0.83) 0.001
30 minute 4.16 (0.88) 5.08 (1.50)
60 minute 2.60 (0.49) 3.08 (0.56)
Pulse rate (1/minute)
Baseline 96.12 (4.69) 96.08 (3.42) 0.001
30 minute 79.48 (3.48) 82.88 (4.34)
60 minute 73.72 (2.79) 77.80 (5.97)
Respiratory rate (1/minute)
Baseline 17.24 (1.34) 17.04 (1.41) 0.172
30 minute 14.52 (1.11) 15.32 (1.60)
60 minute 13.56 (1.34) 14.04 (1.77)
O2 Saturation (%)
Baseline 93.88 (1.79) 93.72 (1.77) 0.933
30 minute 94.28 (1.67) 94.20 (1.64)
60 minute 94.12 (1.59) 94.28 (1.57)
Temperature (Celsius)
Baseline 37.14 (0.30) 37.01 (0.16) 0.071
30 minute 37.06 (0.20) 36.99 (0.13)
60 minute 37.09 (0.28) 37.09 (0.28)
2.8. Outcomes
Severity of patients’ pain was measured by VAS (7) at baseline
as well as 30 and 60 minutes after infusion. The patients’ vi-
tal signs (blood pressure, pulse rate, respiratory rate, and ar-
terial oxygen saturation) as well as possible side effects such
as nausea, vomiting, dizziness, itching and drowsiness were
recorded for all patients at minutes 30 and 60. In the case
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Figure 1: The flowchart of study.
of VAS greater than 5 after 30 minute, additional dose of in-
travenous morphine sulfate was infused in both groups. The
amount of the morphine administered to the patients until
pain relief was recorded as well. Data was recorded by the as-
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jemerg.com
5 Emergency. 2017; 5 (1): e25
Figure 2: Mean pain severity (7) at various times in the two groups. VAS: visual analouge scale.
sistant emergency medicine specialist, who was not aware of
the groupings. Moreover, to check for the vital signs and side
effects, up to 6 hours after the end of the study, the patients
were followed up by checking their blood pressure, heart rate,
respiratory rate, and deep tendinous reflexes. Clinically sig-
nificant pain relief was considered as ≥ 3 score decrease of
pain severity on VAS.
2.9. Statistical analysis
Based on the mean pain scores, in magnesium sulfate and
normal saline groups (2.1 ± 1.8 and 1.2 ± 2.9, respectively)
(10), alpha error of 5%, and the power of 90%, 50 patients
in each group were considered as the sample size. The
study analysis approach was that of intention to treat. Data
were analyzed using STATA 13 software through t-test and re-




100 patients (50 patients per group) were randomly allocated
to two treatment groups. PatientsâĂŹ flowchart is shown in
figure 1. The baseline data for the two groups are shown in
table 1. There was no significant difference between the two
groups regarding baseline characteristics. Although a signif-
icant difference was found in body temperature of the pa-
tients in the two groups, such a difference is clinically neg-
ligible.
3.2. Outcomes
In table 2, the desired outcome of this study in the baseline,
30 and 60 minutes after intervention are compared between
the two groups. Repeated measure ANOVA test showed no
significant difference for systolic blood pressure (p = 0.677),
diastolic blood pressure (p = 0.628), respiratory rate (p =
0.172), oxygen saturation (p = 0.933), and body temperature
(p = 0.071) at various times between the two groups. The
mean pain severity on VAS, however, was significantly differ-
ent in the groups afer intervention (p = 0.001; figure 2 and ta-
ble 2). In addition, mean pulse rate in the magnesium sulfate
group (p = 0.001) was significantly lower than that of standard
protocol group (figure 3). No significant differences in terms
of nausea, vomiting, itching and drowsiness were, observed
between the two groups. Likewise, no cases of dizziness were
reported in the groups. The average additional morphine re-
ceived, in the control group was significantly higher than that
of the magnesium sulfate group (1.56 vs 0.96 mg; p = 0.043).
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Figure 3: Mean pulse rate (20) at various times in the two groups. PR: pulse rate.
4. Discussion:
The findings of present study suggest that adding magne-
sium sulfate to standard protocol of renal colic management
could be effective in reducing the patients’ pain and need
for additional dose of morphine sulfate without disturbing
hemodynamic measures. However, the amounts of these
effects are not clinically significant. Magnesium plays key
roles in several physiological processes. It has been stated
to potentiate lidocaine (7), induce analgesia during spinal
anesthesia (11, 12), improve morphine analgesia (13, 14),
and reduce consumption of postoperative morphine (15, 16).
Numerous studies with diverse doses, routes, and methods
of administration of magnesium have been conducted with
contradictory results (17-19). Examining the impact of low-
dose magnesium sulfate infusions on pain after laparoscopic
cholecystectomy surgery, Kocman et al. (20) found that mag-
nesium sulfate significantly reduces post-operative pain. In
2006, Safdar et al. (21) study showed that a combination
of morphine and ketorolac relief pain better to either drug
alone. Rezae et al. (2014) examined the effect of magnesium
sulfate infusion on pain relief after cesarean section and de-
clared that infusion of 50 mg/kg magnesium sulfate reduces
the pain and diminishes the need for other pain medications
as well (10). Studying the bronchodilating effect of intra-
venous magnesium sulfate in bronchial asthma, Okayama
et al. (22) also found that magnesium sulfate infusion can
bring about rapid and significant dilation of the bronchi in
both mild and severe asthma. Their study showed that mag-
nesium sulfate relaxes the smooth muscles of the bronchial
wall and dilates the ducts. In our study, adding magnesium
sulfate to the standard treatment of patients with renal colic
reduced the severity of pain and decreased the need for addi-
tional morphine. Considering that no side effects have been
reported for using magnesium sulfate, as well as its easy ap-
plication, this drug can be used as an adjunct drug in treat-
ment of patients suffering from renal colic. Simultaneous use
of magnesium sulfate with other drugs can also reduce their
dosage and possible side effects.
5. Limitation
The main limitation of this study was sample size. Due to
small sample size and maybe low statistical power, it is rec-
ommended that further studies with larger sample sizes be
conducted to examine any possible side effects for this drug
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and to confirm or reject the findings of this study.
6. Conclusion:
The results of this study indicated that magnesium sulfate
can be used as an adjunct drug in treatment of patients suf-
fering from renal colic. It can reduce the pain and diminish
the need for additional doses of morphine sulfate without
disturbing hemodynamic measures. However, the amounts
of these effects are not clinically significant.
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